Radnor Capital Management LLC Has $2.79 Million Holdings in Elevance Health, Inc. (NYSE:ELV)

Radnor Capital Management LLC trimmed its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 5.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,565 shares of the company’s stock after selling 425 shares during the period. Radnor Capital Management LLC’s holdings in Elevance Health were worth $2,791,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of ELV. Raelipskie Partnership acquired a new position in Elevance Health during the 3rd quarter worth $26,000. PSI Advisors LLC bought a new stake in shares of Elevance Health during the third quarter worth $27,000. Eastern Bank bought a new position in Elevance Health in the third quarter valued at about $31,000. Dunhill Financial LLC increased its position in Elevance Health by 57.8% in the third quarter. Dunhill Financial LLC now owns 71 shares of the company’s stock worth $37,000 after purchasing an additional 26 shares during the period. Finally, Peterson Financial Group Inc. bought a new stake in Elevance Health during the 3rd quarter worth about $44,000. 89.24% of the stock is owned by institutional investors.

Elevance Health Stock Performance

Shares of ELV opened at $393.21 on Wednesday. The firm has a market cap of $91.19 billion, a P/E ratio of 14.34, a PEG ratio of 1.15 and a beta of 0.84. Elevance Health, Inc. has a twelve month low of $362.21 and a twelve month high of $567.26. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.50 and a current ratio of 1.50. The firm’s 50 day moving average price is $390.48 and its two-hundred day moving average price is $469.30.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Thursday, October 17th. The company reported $8.37 EPS for the quarter, missing the consensus estimate of $9.66 by ($1.29). The company had revenue of $44.72 billion during the quarter, compared to the consensus estimate of $43.47 billion. Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $8.99 earnings per share. On average, analysts forecast that Elevance Health, Inc. will post 32.96 EPS for the current fiscal year.

Insider Transactions at Elevance Health

In other news, EVP Charles Morgan Kendrick, Jr. sold 7,417 shares of the business’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $432.14, for a total value of $3,205,182.38. Following the sale, the executive vice president now owns 8,423 shares of the company’s stock, valued at $3,639,915.22. The trade was a 46.82 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.35% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ELV. UBS Group reduced their target price on shares of Elevance Health from $605.00 to $555.00 and set a “buy” rating on the stock in a research note on Friday, October 18th. Wells Fargo & Company lowered their target price on shares of Elevance Health from $593.00 to $495.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Cantor Fitzgerald cut their price target on Elevance Health from $600.00 to $485.00 and set an “overweight” rating on the stock in a research note on Friday, October 18th. Royal Bank of Canada decreased their price objective on Elevance Health from $585.00 to $478.00 and set an “outperform” rating for the company in a research note on Friday, October 18th. Finally, Stephens reissued an “underperform” rating on shares of Elevance Health in a research note on Friday, October 18th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $536.53.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.